When Negotiated Prices Become The Benchmark: Prior MFPs And The Vanishing Role Of Value Sean D. Sullivan,Peter J. Neumann,andEmma M. Cousin October 8, 2026

https://www.healthaffairs.org/content/forefront/negotiated-prices-become-benchmark-prior-mfps-and-vanishing-role-value?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz--YRFytAZuTDPVfo2MYzRKvAsXZaujpNBR5GkmZ9DDOkSkcVa3ucZaFTCrJODjHA1HUz8QNUq2eg0bSzofNjmopb44n_Q&_hsmi=443478114&utm_source=hasu Previously negotiated Medicare drug prices have quietly become inputs to new negotiations. Each cycle that inherits a prior price moves the program further from any explicit account of what a drug is worth.